Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Johnson & Johnson    JNJ

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 

Johnson & Johnson : J&J Cancer Drug Zytiga Now Backed For Publicly Funded Use In UK

share with twitter share with LinkedIn share with facebook
share via e-mail
0
05/16/2012 | 11:11am CET

The U.K.'s health-care cost-effectiveness regulator Wednesday reversed an earlier decision and approved the publicly funded use of Johnson & Johnson's (JNJ) prostate-cancer pill Zytiga, after the U.S. company cut its price further.

Also known as abiraterone, Zytiga removes the prostate cancer tumor's supply of testosterone, preventing it from growing further and potentially extending a patient's life by more than three months. The medicine was rejected for use in the U.K. in February on grounds its terms of use wouldn't offer value for money.

Andrew Dillon, chief executive of the U.K.'s National Institute for Health and Clinical Excellence, or NICE, Wednesday said the manufacturer subsequently submitted fresh information, including a revised patient access scheme containing a deeper price discount to the National Health Service and more information about which patients would most benefit from its use and how many patients could receive the drug.

"These factors enabled the committee to revise its preliminary recommendation and now recommend the drug for use on the NHS," Dillon said in a statement. "It is an effective treatment, potentially extending life by more than three months, and it also allows patients to be treated at home as it can be taken orally."

Abiraterone costs GBP2,930 for a 30-day supply of 120 tablets. NICE didn't specify the size of the price cut offered by Johnson & Johnson.

Zytiga was approved by U.S. and European drug regulators last year. It is set to generate peak-year sales of $910 million.

-By Sten Stovall, Dow Jones Newswires; +44 207 842 9292; sten.stovall@dowjones.com

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on JOHNSON & JOHNSON
02/24 JOHNSON & JOHNSON : Remarks by President Trump at Signing of Executive Order on ..
02/24 JOHNSON & JOHNSON : Fourth Talcum Powder Lawsuit Heads to Trial in Missouri Ovar..
02/24 JOHNSON & JOHNSON : ex-dividend day
02/23 JOHNSON & JOHNSON : S&P upgrades Google's owner to its second-highest ranking
02/23 JOHNSON & JOHNSON : Anti-diarrhea medication ripe for abuse by opioid addicts, a..
02/22 Genmab and J&J's cancer drug set for blockbuster sales this year
02/21 Icahn buys Bristol-Myers shares, adding to activist pressure
02/21 JOHNSON & JOHNSON : Ford Still Can Repair its Brand in South Africa but it Needs..
02/21 JOHNSON & JOHNSON : Ford still can repair its brand in South Africa but it needs..
02/20 MEDTRONIC : Global High Speed Surgical Drill Market- Medtronic, Johnson and John..
More news
Sector news : Pharmaceuticals - NEC
02/24DJSHIRE : Files 8K - Other Events
02/24DJASTRAZENECA : Hyperkalaemia Drug Clears Scientific Hurdle for European Approval
02/24DJASTRAZENECA : Gets Approval for Drug Treating Hyperkalaemia
02/24 Exclusive - Trump says Republican border tax could boost U.S. jobs
02/23DJPFIZER : Files 8K - Changes Executive Management
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
02/24 UPCOMING EVENTS : J&J And NeuroDerm Put New Delivery Routes To The Test
02/24 A Dividend Portfolio Built From The World's Best Dividend ETFs
02/24 ValueAct Capital Is Going Risk-Off. Right Or Wrong?
02/24 SYNERGY : 3 Scenarios, 1 Choice
02/24 Europe's CHMP backs expanded use of Janssen Biotech's Darzalex
Advertisement
Financials ($)
Sales 2017 74 655 M
EBIT 2017 23 131 M
Net income 2017 18 272 M
Finance 2017 22 793 M
Yield 2017 2,73%
P/E ratio 2017 18,40
P/E ratio 2018 17,25
EV / Sales 2017 4,17x
EV / Sales 2018 3,94x
Capitalization 333 891 M
More Financials
Chart JOHNSON & JOHNSON
Duration : Period :
Johnson & Johnson Technical Analysis Chart | JNJ | US4781601046 | 4-Traders
Full-screen chart
Technical analysis trends JOHNSON & JOHNSON
Short TermMid-TermLong Term
TrendsBullishBullishNeutral
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 22
Average target price 125 $
Spread / Average Target 2,1%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Alex Gorsky Chairman & Chief Executive Officer
Dominic J. Caruso Chief Financial Officer & Vice President
Paulus Stoffels Chief Scientific Officer & Executive VP
Charles O. Prince Independent Director
William David Perez Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON5.63%333 891
ROCHE HOLDING LTD.5.98%210 192
PFIZER INC.4.86%207 902
NOVARTIS AG4.72%202 648
MERCK & CO., INC.11.86%182 412
SANOFI4.38%109 848
More Results